biote Corp. (BTMD) FY2025 10-K Annual Report
biote Corp. (BTMD) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 13, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
biote Corp. FY2025 10-K Analysis
Business Overview
- • Core business: hormone optimization training and Biote-branded dietary supplements sold to Biote-certified practitioners and partnered clinics
- • Strategic emphasis on managing risks related to outsourcing facilities that compound bioidentical hormones, including recent acquisition of Asteria Health (Mar 2024)
Risk Factors
- • Regulatory risk from potential liability and recalls linked to compounded drug formulations via outsourcing facilities, posing reputational harm
- • Macroeconomic exposure from 2.5% revenue decline to $192.2M in 2025 due to slowdown in new clinic additions and procedure volumes
biote Corp. FY2025 Key Financial MetricsXBRL
Revenue
$192M
▼ -2.5% YoY
Net Income
$27M
▲ +756.7% YoY
Operating Margin
18.5%
▲ +246bp YoY
Net Margin
14.1%
▲ +1247bp YoY
ROE
-46.2%
▼ -4322bp YoY
Total Assets
$108M
▼ -12.1% YoY
EPS (Diluted)
$0.74
▲ +722.2% YoY
Operating Cash Flow
$35M
▼ -22.2% YoY
Source: XBRL data from biote Corp. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on biote Corp.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.